|
Study | Country | Year | Project | Initial Treatment | Include patients | End point | Randomized Treatment | Jada Scores |
|
Chi H et al. [8] | Netherlands, China | 2017 | NCT01532843 | ≥12wk ETV or TDF | HBV DNA <2 000 IU/mL, ALT<5 times the upper limit of normal | ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion | NA, NA add-on PEG IFN | 2 |
|
Sun J et al. [9] | China | 2016 | NCT01086085 | 24wk PEG IFN | Non early responders | ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion | PEG IFN, PEG IFN add- on NA | 2 |
|
Brouwer WP et al. [6] | Europe, Asia | 2015 | NCT00877760 | 24wk ETV | ALT >1.3 times the upper limit of normal | ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion | NA, NA add-on PEG IFN | 2 |
|
Xie Q et al. [10] | China | 2014 | NCT00614471 | NA | HBV DNA ≥100 000 copies/mL, ALT >2 but ≤10 times the upper limit of normal | ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion | PEG IFN, NA and PEG IFN add-on NA | 2 |
|
Liu YH et al. [11] | China | 2014 | - | NA | HBV DNA ≥100 000 copies/mL, ALT >2 but ≤10 times the upper limit of normal | ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion | PEG IFN, PEG IFN combined NA | 1 |
|
Ning Q et al. [7] | China | 2014 | OSST | 9-36 months ETV | HBV DNA <1000copies/mL, HBeAg<100PEIU/L | ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion | NA, NA switch PEG IFN | 2 |
|
Lau GK et al. [12] | 16 countries | 2005 | - | NA | HBsAg negative, HBV DNA ≥500 000 copies/mL, ALT >1 but ≤10 times the upper limit of normal | ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion | NA, PEG IFN combined PLA, and PEG IFN combined NA | 3 |
|
Chan HL et al. [13] | Hong Kong | 2005 | - | - | HBV DNA ≥500 000 copies/mL, ALT >1.3 but ≤5 times the upper limit of normal | ALT normalization, HBV DNA undectable, and HBeAg seroconversion | PEG IFN add-on NA, NA | 2 |
|
Janssen HL et al. [14] | 15 countries | 2005 | - | - | ALT >2 times the upper limit of normal | ALT normalization, HBV DNA undectable, HBeAg loss and HBeAg seroconversion | PEG IFN combined NA, PEG IFN combined PLA | 3 |
|